Chemomab Therapeutics (CMMB) reported positive results from a Phase 2 trial of nebokitug, a treatment for primary sclerosing cholangitis and other fibro-inflammatory diseases.
Patients treated with nebokitug exhibited significant changes in several proteins associated with fibrosis, inflammation and immune system activity with the effects increasing at higher doses, the company said Monday in a statement.
The data showed that the nebokitug treatment reduced biological processes tied to fibrosis and inflammation, the company said.
Nebokitug also lowered proteins involved in immune cell movement, inflammatory signals and collagen binding, the company said.
Shares of the company rose 1.5% in recent Monday trading.
Price: 1.33, Change: +0.02, Percent Change: +1.53
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.